Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 4/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.37 |
| ▸ | IL1B | P01584 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707165 | 0.96 | ALDH1A1 (0.45) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL1193030 | 0.84 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL1141884 | 0.84 | RXRA (0.45) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL156398 | 0.84 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL168052 | 0.84 | DDB1 (0.51) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL29416187 | 0.84 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31628652 | 0.84 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL4572292 | 0.84 | CYP4F2 (0.46) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL20818033 | 0.83 | RXRA (0.43) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL22499151 | 0.83 | RXRA (0.40) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-107660204-B | Method for producing indazole derivative | 葛兰素史克知识产权开发有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3303329-B1 | PROCESSES TO MAKE INDAZOLE DERIVATIVES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-3303329-B1 | PROCESSES TO MAKE INDAZOLE DERIVATIVES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-3497100-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-20190161480-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-30 | — | — | US | disclosed |
| US-20190161480-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-05-30 | — | — | US | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2207781-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009146406-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009097446-A1 | PYRAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009042607-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330235-A1 | TRICYCLIC P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PI4KA, PIK3CA | RXRA 4792/4885RXRB 4715/4885RXRG 4670/4885 |
| US-20190161480-A1 | Chemical Compounds | PIK3CA, PIK3CD, PIK3C2B | RXRA 4780/4885RXRB 4775/4885RXRG 4734/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | RXRA 1876/4885RXRB 1724/4885RXRG 1672/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | RXRA 3985/4885RXRB 3323/4885RXRG 3344/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | RXRA 4040/4885RXRB 3427/4885RXRG 3664/4885 |
| US-20220348593-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MTOR | RXRA 4428/4885RXRB 4233/4885RXRG 4083/4885 |
| US-20250388599-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3C2B, PIK3C2A, PIK3R1 | RXRA 1613/4885RXRB 1304/4885RXRG 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.